Tasrif Pharmaceuticals Expands Intellectual Property Around Poliovirus Receptor

Tasrif Pharmaceutical, LLC has secured its second U.S. patent, expanding its intellectual property around the Poliovirus Receptor (CD155/PVR) and strengthening protection for its antibody-based cancer immunotherapy platform.

The portfolio includes a proprietary panel of humanized monoclonal antibodies and antigen-binding fragments, including lead candidate TSRF-786C IgG4 (S241P), humanized using Abzena’s Composite Human Antibody platform.

Tasrif said it is using the CD155-binding platform to develop next-generation therapies, including ADCs, bispecifics, T-cell engagers, CAR-T, and CAR-NK approaches, with related patent applications pending in Japan, Europe, Canada, Australia, and China.

The company reported preclinical evidence of tumor-specific accumulation in a glioblastoma mouse model and is advancing brain-penetrating Anti-CD155 × Anti-Transferrin Receptor bispecific antibodies aimed at crossing the blood-brain barrier for CNS cancers.

For systemic cancers, TSRF-786C has shown sub-nanomolar CD155 binding, target specificity, low immunogenicity in Abzena’s EpiScreen assay, a favorable cytokine-release profile, and non-human primate cross-reactivity supporting planned IND-enabling studies.

Pilot humanized mouse studies in pancreatic and lung cancer also showed TSRF-786C modulated the CD155–DNAM-1 immune axis without altering local PD-1 expression, supporting potential combination strategies with anti-PD-1 therapies.